Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2026-11-16 6:12 pm Sale | 2026-09-30 | 13G | ARBUTUS BIOPHARMA CORP ABUS | Two Seas Capital LP | 8,143,994 4.100% | -10,413,549![]() (-56.11%) | Filing History |
| 2026-11-16 4:20 pm Sale | 2026-09-30 | 13G | ARBUTUS BIOPHARMA CORP ABUS | Whitefort Capital Master Fund, LP | 2,451,033 1.600% | -13,343,228![]() (-84.48%) | Filing History |
| 2026-11-16 3:27 pm Purchase | 2026-09-30 | 13G | ARBUTUS BIOPHARMA CORP ABUS | NOMURA HOLDINGS INC NMR | 14,512,000 7.300% | 14,512,000![]() (New Position) | Filing History |
| 2026-10-27 5:25 pm Purchase | 2026-09-30 | 13G | ARBUTUS BIOPHARMA CORP ABUS | BlackRock Inc. BLK | 14,331,732 7.200% | 3,941,432![]() (+37.93%) | Filing History |
| 2026-10-07 4:35 pm Purchase | 2026-09-30 | 13G | ARBUTUS BIOPHARMA CORP ABUS | MORGAN STANLEY MS | 18,682,708 12.200% | 1,295,310![]() (+7.45%) | Filing History |
| 2026-10-05 9:02 pm Sale | 2026-10-01 | 13D | ARBUTUS BIOPHARMA CORP ABUS | Roivant Sciences Ltd. ROIV | 29,880,079 19.500% | -8,967,383![]() (-23.08%) | Filing History |
| 2026-09-04 6:32 pm Unchanged | 2026-09-04 | 13G | ARBUTUS BIOPHARMA CORP ABUS | Whitefort Capital Master Fund, LP | 15,794,261 8.000% | 0 (Unchanged) | Filing History |
| 2026-08-12 3:02 pm Sale | 2026-06-30 | 13G | ARBUTUS BIOPHARMA CORP ABUS | MORGAN STANLEY MS | 17,387,398 8.800% | -8,522,939![]() (-32.89%) | Filing History |
| 2026-05-15 5:29 pm Purchase | 2026-03-31 | 13G | ARBUTUS BIOPHARMA CORP ABUS | Two Seas Capital LP | 18,557,543 9.400% | 5,968,385![]() (+47.41%) | Filing History |
| 2026-04-28 5:54 pm Unchanged | 2026-04-24 | 13D | ARBUTUS BIOPHARMA CORP ABUS | Whitefort Capital Master Fund, LP | 15,794,261 8.000% | 0 (Unchanged) | Filing History |
| 2026-04-13 7:56 pm Purchase | 2026-04-10 | 13D | ARBUTUS BIOPHARMA CORP ABUS | Whitefort Capital Master Fund, LP | 15,794,261 8.100% | 2,486,294![]() (+18.68%) | Filing History |
| 2026-02-17 4:21 pm Purchase | 2025-12-31 | 13G | ARBUTUS BIOPHARMA CORP ABUS | Two Seas Capital LP | 12,589,158 6.500% | 2,145,841![]() (+20.55%) | Filing History |
| 2026-02-11 1:45 pm Purchase | 2025-12-31 | 13G | ARBUTUS BIOPHARMA CORP ABUS | MORGAN STANLEY MS | 25,910,337 13.500% | 4,385,676![]() (+20.38%) | Filing History |
| 2025-08-13 5:40 pm Purchase | 2025-06-30 | 13G | ARBUTUS BIOPHARMA CORP ABUS | Two Seas Capital LP | 10,443,317 5.400% | 2,055,929![]() (+24.51%) | Filing History |
| 2025-02-25 07:19 am Unchanged | 2025-02-21 | 13D | ARBUTUS BIOPHARMA CORP ABUS | Roivant Sciences Ltd. ROIV | 38,847,462 20.500% | 0 (Unchanged) | Filing History |
| 2025-02-21 09:00 am Purchase | 2025-02-20 | 13D | ARBUTUS BIOPHARMA CORP ABUS | Whitefort Capital Master Fund, LP | 13,307,967 7.000% | 440,000![]() (+3.42%) | Filing History |
| 2025-02-18 5:21 pm Unchanged | 2025-02-18 | 13D | ARBUTUS BIOPHARMA CORP ABUS | Roivant Sciences Ltd. ROIV | 38,847,462 20.500% | 0 (Unchanged) | Filing History |
| 2025-02-03 3:26 pm Purchase | 2024-12-31 | 13G | ARBUTUS BIOPHARMA CORP ABUS | MORGAN STANLEY MS | 21,524,661 11.400% | 2,132,173![]() (+10.99%) | Filing History |
| 2024-11-14 08:41 am Sale | 2024-09-30 | 13G | ARBUTUS BIOPHARMA CORP ABUS | Two Seas Capital LP | 8,387,388 4.400% | -654,539![]() (-7.24%) | Filing History |
| 2024-06-10 4:50 pm Purchase | 2024-05-31 | 13G | ARBUTUS BIOPHARMA CORP ABUS | MORGAN STANLEY MS | 19,392,488 10.300% | 17,954,224![]() (+1248.33%) | Filing History |

